SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the ...
External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative Database This study used Optum's deidentified Market ...
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...
As a growing number of never-smokers are being diagnosed with lung cancer, new research aims to better understand the genetic risk, or predisposition, for developing lung cancer — and study ...
In this prospective cohort study, duration-based criteria reduced racial disparities in lung cancer screening eligibility, increasing access for minority groups compared with current US guidelines. 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback